Hopes rise on coronavirus drug remdesivir

www.nature.com /articles/d41586-020-01295-8
Heidi Ledford
7-8 minutes
A patient at the intensive care unit receives treatment from two hospital workers in Hefei, China

Coronavirus causes severe respiratory illness in some people.Credit: Zhang Yazi/China News Service via Getty

An experimental drug — and one of the world’s best hopes against COVID-19 — could shorten the time to recovery from coronavirus infection, according to the largest and most rigorous clinical trial of the compound.

The experimental drug, called remdesivir, interferes with replication of some viruses, including the SARS-CoV-2 virus responsible for the current pandemic. On 29 April, Anthony Fauci, director of the US National Institute of Allergy and Infectious Disease (NIAID), announced that a clinical trial of more than a thousand people showed that people taking remdesivir recovered in 11 days on average, compared to 15 days for those on a placebo.

A Nobel Laureate Said the New Coronavirus Was Made in a Lab. He's Wrong. - The Wire Science

22/04/2020
5-6 minutes
Luc Montagnier during the TV interview. Photo: YouTube.

...It is surprising to have a scientist of Montagnier’s stature utter such questionable statements – although Montagnier himself is a controversial figure. Among other causes, he has supported anti-vaxxers, homeopathy and a silly claim that DNA emits “electromagnetic waves”....

The 2008 Nobel Laureate for physiology or medicine from France, Luc Antoine Montagnier, caught the media’s attention when he recently endorsed a COVID-19 conspiracy theory – that the virus is human-made. His proclamation was subsequently magnified by various news outlets, including many in India (e.g., The Week, The Hindu Businessline, and Times of India).

Montagnier argued during a TV interview with a French TV channel that elements of the HIV-1 retrovirus, which he co-discovered in 1983, can be found in the genome of the new coronavirus. He also said elements of the “malaria germ” – the parasite Plasmodium falciparum – can also be seen in the virus’s genome.

His full quote: “We were not the first since a group of Indian researchers tried to publish a study which showed that the complete genome of this coronavirus [has] sequences of another virus, which is HIV.”

The Science behind How Coronavirus Tests Work

Jeffery DelViscio
8-10 minutes
From Scientific American
So you think you may have COVID-19, and you want to get tested.

Your first problem might be finding a test, depending on where you live and how sick you currently are.

A recent survey conducted with administrators from 323 hospitals across the United States found...

Quote: “Hospitals reported that severe shortages of testing supplies and extended waits for test results limited hospitals’ ability to monitor the health of patients and staff....”

Adding: “... they were unable to keep up with testing demands because they lacked complete kits and/or the individual components ... used to detect the virus.”

But let’s say that you can actually get a test for COVID-19.

Will antibody tests for the coronavirus really change everything?

Smriti Mallapaty
10-13 minutes
COVID-19 coronavirus antibody test kits.
More at  www.nature.com /articles/d41586-020-01115-z
Antibody tests might be used to help stem the COVID-19 pandemic — but first must overcome several hurdles.Credit: Greg Baker/AFP/Getty

British Prime Minister Boris Johnson called them a ‘game changer’. Antibody tests have captured the world’s attention for their potential to help life return to normal by revealing who has been exposed, and might now be immune, to the new coronavirus.

Dozens of biotech companies and research laboratories have rushed to produce the blood tests. And governments around the world have bought millions of kits, in the hope that they could guide decisions on when to relax social-distancing measures and get people back to work. Some have even suggested that the tests could be used as an ‘immunity passport’, giving the owner clearance to interact with others again.

More Encouraging Signs for Remdesivir as COVID-19 Treatment

Alice Park
5-7 minutes
Comment from the owner: What a pitty TIME...
Researchers at University of Chicago reported promising results from a small study of remdesivir in treating people with COVID-19.

The findings were not published in a peer-reviewed journal, but revealed in an internal video discussion of the drug trial among University of Chicago faculty that was obtained by STAT.

The study included 125 people with COVID-19, all of whom were treated with the remdesivir, which is not currently approved in the U.S. for treating any disease. Of the 125 patients in the Chicago study, 113 had severe disease, meaning they had difficulty breathing. In the video discussion, Kathleen Mullane, a professor of medicine at the university who is overseeing the trial, said most of the patients taking the drug had improved enough to be discharged from the hospital, and only two died. Mullane was not available to discuss the results, but in a statement, a university spokesperson said “Partial data from an ongoing clinical trial is by definition incomplete and should never be used to draw conclusions about the safety or efficacy of a potential treatment that is under investigation. In this case, information from an internal forum for research colleagues concerning work in progress was released without authorization. Drawing any conclusions at this point is premature and scientifically unsound.”

COVID-19: What we must do to prevent a global depression

Klaus Schwab Founder and Executive Chairman, World Economic Forum
12-15 minutes

No diagrams & photos, original in the link.
Without a vaccine or effective COVID-19 treatment, we could face continued infections and death until at least the end of 2020.
To prevent further spread of coronavirus, we must monitor what fraction of the population has been in contact with the virus and is potentially immune.
To prevent an economic collapse, governments will need to take on large and unprecedented roles in securing business continuity and jobs.
A few months in, it is still hard to grasp the scale and scope of COVID-19’s global impact. A third of the world population is under some sort of “lockdown.” Over 200 countries are affected, and the number of new cases and deaths in many places are still growing exponentially. All the while, a second crisis, in the form of an economic recession, is underway.

The COVID-19 vaccine development landscape

Stephen Mayhew
10-13 minutes
 (Figures and Tables ommited, for full article go here)
The genetic sequence of SARS-CoV-2, the coronavirus that causes COVID-19, was published on 11 January 2020, triggering intense global R&D activity to develop a vaccine against the disease. The scale of the humanitarian and economic impact of the COVID-19 pandemic is driving evaluation of next-generation vaccine technology platforms through novel paradigms to accelerate development, and the first COVID-19 vaccine candidate entered human clinical testing with unprecedented rapidity on 16 March 2020.